Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune… Read more
Raphael Pharmaceutical Inc. (RAPH) - Total Assets
Latest total assets as of September 2025: $7.00K USD
Based on the latest financial reports, Raphael Pharmaceutical Inc. (RAPH) holds total assets worth $7.00K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Raphael Pharmaceutical Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Raphael Pharmaceutical Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Raphael Pharmaceutical Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Raphael Pharmaceutical Inc.'s total assets of $7.00K consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Raphael Pharmaceutical Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Raphael Pharmaceutical Inc.'s current assets represent 92.6% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 70.4% of total assets in 2024, up from 29.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Raphael Pharmaceutical Inc. Competitors by Total Assets
Key competitors of Raphael Pharmaceutical Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Raphael Pharmaceutical Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Raphael Pharmaceutical Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Raphael Pharmaceutical Inc. is currently not profitable relative to its asset base.
Raphael Pharmaceutical Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.07 | 1.44 |
| Quick Ratio | 0.00 | 0.07 | 1.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.27 Million | $ -618.00K | $ 128.00K |
Raphael Pharmaceutical Inc. - Advanced Valuation Insights
This section examines the relationship between Raphael Pharmaceutical Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 304.45 |
| Latest Market Cap to Assets Ratio | 427.70 |
| Asset Growth Rate (YoY) | -88.7% |
| Total Assets | $27.00K |
| Market Capitalization | $11.55 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Raphael Pharmaceutical Inc.'s assets at a significant premium ( 427.70x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Raphael Pharmaceutical Inc.'s assets decreased by 88.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Raphael Pharmaceutical Inc. (2020–2024)
The table below shows the annual total assets of Raphael Pharmaceutical Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $27.00K | -88.70% |
| 2023-12-31 | $239.00K | -28.23% |
| 2022-12-31 | $333.00K | -21.09% |
| 2021-12-31 | $422.00K | +30.65% |
| 2020-12-31 | $323.00K | -- |